$543 Million is the total value of KPCB XIII Associates, LLC's 4 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PGNY | Sell | Progyny, Inc. | $436,961,000 | +18.3% | 7,406,115 | -10.7% | 80.41% | +5.9% |
| LUNG | Pulmonx Corporation | $43,898,000 | -3.5% | 994,971 | 0.0% | 8.08% | -13.6% | |
| EPZM | Epizyme, Inc. | $31,895,000 | -4.6% | 3,838,166 | 0.0% | 5.87% | -14.6% | |
| TMDX | TransMedics Group, Inc. | $30,632,000 | -20.0% | 923,221 | 0.0% | 5.64% | -28.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-07-28
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Progyny, Inc. | 8 | Q3 2023 | 96.0% |
| Pulmonx Corporation | 8 | Q3 2023 | 14.3% |
| Epizyme, Inc. | 4 | Q3 2021 | 6.9% |
| TransMedics Group, Inc. | 4 | Q3 2021 | 7.9% |
| Movella Holdings Inc. | 3 | Q3 2023 | 4.9% |
| Rapid Micro Biosystems, Inc. | 1 | Q3 2021 | 0.1% |
View KPCB XIII Associates, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-12 |
| 3 | 2023-02-17 |
| 13F-HR | 2023-02-07 |
| 13F-HR | 2021-10-25 |
| 13F-HR | 2021-07-28 |
| 4 | 2021-06-22 |
| 13F-HR | 2021-05-13 |
| 4 | 2021-04-19 |
View KPCB XIII Associates, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.